Predicting liver cancer risk in MASH patients using proteins
Part of Cancer, Digestive system clinical trials.
This study looks at how certain proteins in the blood might help predict the risk of developing liver cancer (HCC) in people with MASH (a type of fatty liver disease with inflammation). Researchers will follow patients with MASH to see who develops liver cancer and who doesn't.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had a liver biopsy that showed MASH (fatty liver with inflammation and liver cell damage)
- You have not had more than 1 alcoholic drink per day if you are a woman or 2 drinks per day if you are a man
- You do not have hepatitis B, C, or other major liver diseases (like autoimmune hepatitis or genetic liver conditions)
- You are not under legal guardianship or judicial protection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
This trial tests an experimental gene therapy (VV-14303) given as a single injection into the muscle to treat MASH, a common type of fatty liver disease with inflammation. The study will check if the treatment is safe and helps improve liver health.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Hear when a new MASH-related HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.